A Semaglutide dose needs some context
Dear reader,
A search for a semaglutide dose can turn up a lot of numbers very quickly. I'd pause at the words around them: which product, for which condition, and in which study? The number makes more sense with its name tag still on.
A study tells us what researchers tested. A prescriber decides what fits a person's health history and treatment goal. Here are two examples worth understanding before comparing numbers online.
Two studies, two different questions
In a type 2 diabetes trial called SUSTAIN 1, researchers tested weekly semaglutide injections of 0.5 mg or 1.0 mg. Semaglutide was studied alone in adults with type 2 diabetes. At 30 weeks, HbA1c and body weight fell more than with placebo, a treatment without the active drug. HbA1c is a marker of average blood sugar over about three months.
In a weight-management trial called STEP 1, researchers tested semaglutide injections with a target of 2.4 mg once weekly against placebo. These adults didn't have diabetes; they had obesity, or overweight with a related health condition. Both groups had lifestyle support.
Neither trial establishes equivalent safety or effectiveness for a compounded preparation. Those aren't competing answers to “What's the best dose?” They describe different research questions and different groups of people. I'd ask which evidence fits the reason treatment is being considered, before asking about a number.
A tablet number isn't an injection number
Semaglutide also comes in tablets. The pharmacology reference describes low absorption by mouth: only a small part reaches the blood. That makes a straight comparison with an injection's milligram figure misleading.
The exact product matters here. “Semaglutide tablet” doesn't name the whole preparation or explain its instructions. A product-specific question belongs with the prescriber, rather than a calculation copied from a web page.
Side effects are part of the decision
Digestive side effects in the weight-management trials often appeared during the gradual dose increases used by researchers. Most were mild or moderate and temporary. That pattern doesn't tell someone to copy a research schedule or wait out severe symptoms.
The Wegovy (semaglutide injection and tablets) label also warns about severe digestive reactions, pancreatitis and gallbladder problems. Pancreatitis means inflammation of the pancreas. I'd want the follow-up plan to cover problems as well as progress.
Device units raise another question
For compounded injections, the FDA has reported dose mistakes involving different concentrations and confusion over measurements. Concentration means how much medicine is in a given volume. Device units alone don't identify the amount of semaglutide.
Compounded medicines aren't FDA-approved. For a particular preparation or unclear measurement, the useful next conversation is with the prescriber or dispensing pharmacist. This page can't check a label or a device in your hands.
P.S. “What is the exact product, and what would make us reconsider the plan?” I'd want both answers written down.